




Draft EMANS to 2028 and plans for stakeholder engagement

11th Industry Standing Group (ISG) - 21 November 2024




European Medicines Agencies Network (EMAN) Strategy to 2028

STRATEGIC FOCUS AREAS



Steps to review and update EMANS to 2028



EMAN strategy to 2028: public consultation

- **Aim:**
 - Promote transparency and allow similar level of inclusivity/equal opportunity as for previous Network strategies
 - Stimulate visibility, awareness and positive perception of the updated strategy
- **2-month public consultation (9 October – 30 November 2024)**
 - Released final draft EMAN strategy together with a predefined template for submission of comments (EUSurvey) and release reflection paper as a background document
- **Multi-stakeholder workshop early February 2025**

Proposed goals for EMANS to 2028

Current draft

Theme 1: Accessibility




Optimise the path to accessibility by working with other decision makers (HTA bodies and payers)



Deepen engagement with healthcare policy makers on initiatives and research relevant to sustain health technology accessibility


Theme 2: Leveraging data, digitalisation and artificial intelligence



Maximise the generation, interoperability, use and exchange of data to support EU decision-making



Leverage digitalisation, experimentation and innovation to deliver optimised regulatory processes



Realise the network vision on AI across all EMANS focus areas

Theme 3: Regulatory science, innovation and competitiveness



Promote the integration of advancing science and technology in medicines development and manufacturing




Foster generation of high quality and impactful evidence with particular focus on clinical trials



Promote stakeholder cooperation to accelerate the translation of innovation into therapies, facilitate the repurposing of existing therapies and increase EU competitiveness

Theme 4: Antimicrobial resistance and other health threats



Contribute to responsible use of antimicrobials and effective antimicrobial stewardship using a One Health approach



Support development of new antimicrobial agents and alternatives to the use of antimicrobials in collaboration with international partners



Strengthen regulatory preparedness for health threats

Theme 5: Availability and supply of medicines



Strengthen the availability of medicines to protect public and animal health



Reinforce the oversight and protection of the supply chain and increase inspector capacity

Theme 6: Sustainability of the network



Reinforce the scientific and regulatory capacity and capability of the network



Establish a shared operating model to support network activities and collaboration



Strengthen public and stakeholder engagement and global convergence with international partners

Next steps

EMAN strategy to 2028: actions post public consultation

- ❑ Closure of consultation on **30 November 2024**
- ❑ EMA/HMA compilation and analysis of comments in **December 2024**
- ❑ Review of updated EMAN strategy by Theme Teams **January 2025**
- ❑ Multi-stakeholder workshop to present and discuss finalised strategy in **February 2025**
- ❑ Adoption by HMA: **mid-March 2025** by written procedure
- ❑ Adoption by EMA MB: **13 March 2025** MB meeting
- ❑ Publication thereafter

Any questions?

Further information

See websites for contact details

Heads of Medicines Agencies www.hma.eu
European Medicines Agency www.ema.europa.eu

The European Medicines Agency is
an agency of the European Union

